.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

LAMISIL Drug Profile

« Back to Dashboard
Lamisil is a drug marketed by Novartis and Glaxosmithkline Cons and is included in eight NDAs. It is available from four suppliers.

The generic ingredient in LAMISIL is terbinafine. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. There is one tentative approval for this compound. Additional details are available on the terbinafine profile page.

Summary for Tradename: LAMISIL

Patents:0
Applicants:2
NDAs:8
Suppliers / Packagers: see list4
Bulk Api Vendors: see list127
Clinical Trials: see list10
Patent Applications: see list5,369
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LAMISIL at DailyMed

Pharmacology for Tradename: LAMISIL

Ingredient-typeAllylamine
Drug ClassAllylamine Antifungal
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
LAMISIL
terbinafine hydrochloride
TABLET;ORAL020539-001May 10, 1996RXYesYes► subscribe► subscribe
Novartis
LAMISIL
terbinafine hydrochloride
CREAM;TOPICAL020192-001Dec 30, 1992DISCNNoNo► subscribe► subscribe
Novartis
LAMISIL
terbinafine hydrochloride
GRANULE;ORAL022071-001Sep 28, 2007RXYesNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LAMISIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons
LAMISIL
terbinafine
GEL;TOPICAL020846-001Apr 29, 19984,680,291► subscribe
Glaxosmithkline Cons
LAMISIL
terbinafine
GEL;TOPICAL020846-001Apr 29, 19985,856,355*PED► subscribe
Novartis
LAMISIL
terbinafine hydrochloride
CREAM;TOPICAL020980-001Mar 9, 19994,755,534*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc